Streetbeat News

Products Services

MSFT

RUM

Rumble has launched an app for Xbox, expanding its availability for streaming live and on-demand content. Users can now access Rumble on Xbox, Apple TV, Roku, Amazon Fire TV, LG Smart TVs, and Samsung TV apps.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 1:02 pm

ICU

NUWE

Nuwellis has announced the first patient treated with its newly launched QUELIMMUNE therapy at Cincinnati Children's Hospital. The therapy, manufactured for SeaStar Medical and licensed by Nuwellis, targets pediatric acute kidney injury (AKI) patients with sepsis requiring kidney replacement therapy.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 1:01 pm

MSFT

Microsoft is experiencing a mixed fiscal Q4, with some partner metrics slipping, but its AI strategy is showing significant promise. Despite a slight miss in partner metrics, growth expectations remain strong, and Microsoft's AI ventures, particularly M365 Copilot and Azure OpenAI Service, are thriving. JPMorgan analyst Mark R. Murphy remains cautiously optimistic about Microsoft's future, emphasizing its strategic position in AI.

Portfolio Pulse from Surbhi Jain

July 26, 2024 | 12:57 pm

PMN

ProMIS Neurosciences reported positive top-line data from its Phase 1a clinical trial of PMN310, showing a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers. The results suggest potential for target engagement in Alzheimer's disease patients.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:38 pm

SMCI

VCIG

VCI Global has announced its entry into an AI computing alliance led by Enlight and Supermicro. The partnership includes Fortinet, UNIC Technology, and others to establish AI computing centers and advance the AI ecosystem.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:37 pm

PMN

ProMIS Neurosciences Inc. (NASDAQ:PMN) announced a private placement financing of up to $122.7 million to support the development of its novel antibody PMN310 for Alzheimer's Disease. The financing includes an upfront $30.3 million and up to an additional $92.4 million tied to the exercise of warrants. The proceeds are expected to support the company beyond the 6-month and 12-month data from the PMN310 Phase Ib study.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:34 pm

CVM

CEL-SCI shares are trading higher following the announcement of positive results from a bias analysis of its Phase 3 study of Multikine, which showed a significant reduction in the 5-year risk of death in its target population.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:29 pm

CVM

CEL-SCI Corporation (NYSE:CVM) reported positive results from a bias analysis for its Phase 3 study of Multikine, a cancer immunotherapy for head and neck cancer. The analysis showed no bias, supporting the efficacy results, and Multikine cut the 5-year risk of death by half compared to control.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:24 pm

HOOD

Floki (CRYPTO: FLOKI) has been listed on Bitstamp, Europe's oldest and largest cryptocurrency exchange. This listing has generated optimism among traders, who believe Floki is well-positioned to follow Dogecoin's movements. The coin has outperformed other meme coins like Shiba Inu and Pepe over the past 30 days.

Portfolio Pulse from Khyathi Dalal

July 26, 2024 | 12:24 pm

CLLS

Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:20 pm